Cargando…

RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer

Tyrosine kinase inhibitors are effective treatments for non-small-cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) mutations. However, relapse typically occurs after an average of 1 year of continuous treatment. A fundamental histological transformation from NSCLC to small-cel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Niederst, Matthew J., Sequist, Lecia V., Poirier, John T., Mermel, Craig H., Lockerman, Elizabeth L., Garcia, Angel R., Katayama, Ryohei, Costa, Carlotta, Ross, Kenneth N., Moran, Teresa, Howe, Emily, Fulton, Linnea E., Mulvey, Hillary E., Bernardo, Lindsay A., Mohamoud, Farhiya, Miyoshi, Norikatsu, VanderLaan, Paul A., Costa, Daniel B., Jänne, Pasi A., Borger, Darrell R., Ramaswamy, Sridhar, Shioda, Toshi, Iafrate, Anthony J., Getz, Gad, Rudin, Charles M., Mino-Kenudson, Mari, Engelman, Jeffrey A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Pub. Group 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4357281/ https://www.ncbi.nlm.nih.gov/pubmed/25758528 http://dx.doi.org/10.1038/ncomms7377

Ejemplares similares

Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition
por: Hata, Aaron N, et al.
Publicado: (2016)

Cardiac Risk-Informed Treatment of EGFR-Mutant Lung Cancer With Osimertinib
por: Piper-Vallillo, Andrew J., et al.
Publicado: (2019)

B-Cell Infiltrate in the Tumor Microenvironment Is Associated With Improved Survival in Resected Lung Adenocarcinoma
por: Dagogo-Jack, Ibiayi, et al.
Publicado: (2023)

Significance of tumor spread through air spaces (STAS) in lung cancer from the pathologist perspective
por: Mino-Kenudson, Mari
Publicado: (2020)

Germline mutations and developmental mosaicism underlying EGFR-mutant lung cancer
por: Burr, Risa, et al.
Publicado: (2023)

Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized?
por: Sehgal, Kartik, et al.
Publicado: (2020)

Diffuse Lung Metastases in EGFR-Mutant Non-Small Cell Lung Cancer
por: Digumarthy, Subba R., et al.
Publicado: (2019)

Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?
por: Mino-Kenudson, Mari
Publicado: (2016)

Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer
por: Dagogo-Jack, Ibiayi, et al.
Publicado: (2018)

ALK Deletion Exons 2 to 19: Case Report of a Rare ALK Inhibitor–Responsive Lung Cancer Driver Oncogene
por: Schoepflin, Zachary R., et al.
Publicado: (2023)

Revolving Door of Histologic Transformation—Tumor Heterogeneity Complicating the Management of EGFR-Mutated Lung Adenocarcinoma: A Case of Jekyll and Hyde
por: Wysota, Michael, et al.
Publicado: (2020)

Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity
por: Marcar, Lynnette, et al.
Publicado: (2019)

Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer
por: Raoof, Sana, et al.
Publicado: (2019)

EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates
por: Sentana-Lledo, Daniel, et al.
Publicado: (2023)

P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer
por: Katayama, Ryohei, et al.
Publicado: (2015)

CCAAT/Enhancer Binding Protein β Is Dispensable for Development of Lung Adenocarcinoma
por: Cai, Yi, et al.
Publicado: (2015)

Clinicopathologic Characteristics and Outcomes for Patients With KRAS G12D-Mutant NSCLC
por: Cooper, Alissa J., et al.
Publicado: (2022)

A Role of Three-Dimensional (3D)-Reconstruction in the Classification of Lung Adenocarcinoma
por: Onozato, Maristela L., et al.
Publicado: (2012)

Invariant Natural Killer T-Cells and Total CD1d Restricted Cells Differentially Influence Lipid Metabolism and Atherosclerosis in Low Density Receptor Deficient Mice
por: VanderLaan, Paul A., et al.
Publicado: (2019)

Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways
por: Rothenberg, S Michael, et al.
Publicado: (2015)

Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine
por: Dias-Santagata, Dora, et al.
Publicado: (2010)

EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors
por: Vasconcelos, Pedro E.N.S., et al.
Publicado: (2020)

Digital Image Analysis for Estimating Stromal CD8+ Tumor-Infiltrating Lymphocytes in Lung Adenocarcinoma
por: Jhun, Iny, et al.
Publicado: (2021)

Assessing invasiveness of subsolid lung adenocarcinomas with combined attenuation and geometric feature models
por: de Margerie-Mellon, Constance, et al.
Publicado: (2020)

Protease inhibitor Camostat Mesyalte blocks wild type SARS-CoV-2 and D614G viral entry in human engineered miniature lungs
por: Wu, Tong, et al.
Publicado: (2022)

Incidence of Radiation Therapy Among Patients Enrolled in a Multidisciplinary Pulmonary Nodule and Lung Cancer Screening Clinic
por: Milligan, Michael G., et al.
Publicado: (2022)

Safety and Success of Repeat Lung Needle Biopsies in Patients with Epidermal Growth Factor Receptor‐Mutant Lung Cancer
por: Fintelmann, Florian J., et al.
Publicado: (2019)

Efficacy and Tolerability of ALK/MET Combinations in Patients With ALK-Rearranged Lung Cancer With Acquired MET Amplification: A Retrospective Analysis
por: Dagogo-Jack, Ibiayi, et al.
Publicado: (2023)

EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6
por: Wu, Yi-Long, et al.
Publicado: (2017)

KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer
por: Krall, Elsa B, et al.
Publicado: (2017)

ALK (D5F3) CDx: an immunohistochemistry assay to identify ALK-positive NSCLC patients
por: Uruga, Hironori, et al.
Publicado: (2018)

Correction: KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer
por: Krall, Elsa Beyer, et al.
Publicado: (2017)

CD1d Selectively Down Regulates the Expression of the Oxidized Phospholipid-Specific E06 IgM Natural Antibody in Ldlr(−/−) Mice
por: Biswas, Tapan K., et al.
Publicado: (2020)

Role of sex in lung cancer risk prediction based on single low-dose chest computed tomography
por: Simon, Judit, et al.
Publicado: (2023)

Determining malignancy in CT guided fine needle aspirate biopsy of subsolid lung nodules: Is core biopsy necessary?
por: Kiranantawat, Nantaka, et al.
Publicado: (2019)

Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care
por: Kodack, David P., et al.
Publicado: (2017)

Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non–small-cell Lung Cancer
por: Sehgal, Kartik, et al.
Publicado: (2021)

Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET-Amplified Non–Small Cell Lung Cancer: TATTON
por: Hartmaier, Ryan J., et al.
Publicado: (2023)

Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6)
por: Wu, Yi-Long, et al.
Publicado: (2017)

Effectiveness of peer teaching in medical education: medical student’s perspective
por: Omar, Farhiya, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_sp18il2va0bpr8u7v2ste1jj1j